Socio-economic status and the therapeutic effectiveness of antihypertensive treatment - the design of the LEO study

Authors: Schmidt, A.C.1; Bramlage, P.2; Lichtenthal, A.3; Eckert, M.4; Scholze, J.1

Source: Current Medical Research and Opinion, Volume 23, Number 8, August 2007 , pp. 1987-1995(9)

Publisher: Informa Healthcare

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Objective: The risk of arterial hypertension and subsequent cardiovascular disease morbidity and mortality increases with low socio-economic status (SES). Even small differences in blood pressure, whether untreated or despite treatment, account for this substantial difference. Most of the increased risk in the low socio-economic group is due to traditional cardiovascular risk factors such as overweight and obesity, alcohol consumption and a sedentary life style. Intense treatment of arterial hypertension has been shown to overcome these prognostic inequalities. Therefore, drugs with high efficacy, optimal treatment adherence and a low potential for drug-related side effects are needed in order to reduce the cardiovascular risk burden of patients with a low SES. The angiotensin receptor blocker (ARB) olmesartan will be used to investigate the effectiveness of this drug in different socio-economic classes.

Research design and methods: The LEO (Long-term Effectiveness of Olmesartan in different Socioeconomic groups) study is a large observational long-term study which has been set up to test the effectiveness of olmesartan within this context. The study has a matched-pairs design (1403 patients in both the low and the high socio-economic classes).

Main outcome measures: The LEO study will test whether this regimen can reduce the SES-related difference in long-term blood pressure control and compliance in the low SES population.

Conclusions: The study may generate valuable information about the antihypertensive effectiveness of olmesartan alone or in combination with hydrochlorothiazide in different socio-economic classes. It will further test whether the drug helps to reduce the inherent inequalities in cardiovascular prognosis between different socio-economic groups.

Current status: The study commenced in July 2007. Results are anticipated in December 2008.

Keywords: COMPLIANCE; EFFECTIVENESS; HYPERTENSION; PERSISTENCE; SOCIO-ECONOMIC CLASS; STUDY DESIGN

Document Type: Research article

DOI: 10.1185/030079907X226078

Affiliations: 1: Charité-Universitaetsmedizin, Department of Internal Medicine, Outpatient Clinic, Berlin, Germany 2: Institute for Clinical Pharmacology, Medical Faculty Carl-Gustav Carus, Technical University Dresden, Dresden, Germany 3: Berlin-Chemie AG, Medicine & Research, Cardiovascular Dept., Berlin, Germany 4: SIMW GmbH, Wegberg, Germany

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$51.50 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A